10 June 2021
Dear world: meet ELOF1 – the newly discovered core factor in the TC-NER pathway
Damaged DNA is a problem for cells. DNA replication and transcription are hampered if the DNA template is damaged. Moreover, accumulating DNA damage is one of the hallmarks of cancer. Luckily our cells are equipped with machineries to fix damaged DNA. Until now, we only knew three core factors that could recognize DNA damage-stalled RNA polymerase: CSA, CSB and UVSSA. Using CRISPR/Cas9 technology Oncode Investigator Jurgen Marteijn’s new research has identified a fourth core factor, called ELOF1. The results of this research are now published in Nature Cell Biology.
8 June 2021
Oncode Investigators Karin de Visser and Wim Vermeulen elected to the prestigious EMBO membership
Oncode Investigators Karin de Visser (NKI) and Wim Vermeulen (ErasmusMC) are part of the 64 newly elected life scientists to the prestigious EMBO membership this year. The membership recognizes outstanding achievements in the life sciences and members are actively involved in the EMBO organization and beyond.
7 June 2021
The development of novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors
Researchers from the group of Oncode Investigator Wouter de Laat (Hubrecht Institute), in collaboration with biotech company Cergentis and lymphoma experts of 5 Dutch hospitals, developed a novel technology for improved detection of clinically relevant chromosomal rearrangements in tumors. The method, FFPE-TLC technology, promises to improve diagnostics for lymphoma and may also be relevant for rearrangement detection in other cancers such as sarcoma and lung- and prostate cancer.
4 June 2021
2020: Accelerating to Full Speed
The year 2020 was extraordinary for everyone. Although COVID-19 also affected Oncode, we are proud to share the successes we achieved in 2020. By further building on our three pillars - scientific excellence, collaboration, and valorization - all the hard work of our community in the last years starts to bear fruits.
2 June 2021
Researchers find new method to reduce the risk of developing colon cancer
The team of Oncode Investigator Louis Vermeulen (Amsterdam UMC, location AMC) has used organoid technology and the application of lithium to discover how the chance of polyps forming in the intestine, and thus the development of colorectal cancer, can be reduced. Competition between stem cells in the gut plays a key role in this. The results appeared in the leading journal Nature today.
27 May 2021
New CPoC grant awarded: GLOW - GLioblastoma targeted treatment Option maximisation by Wgs
Oncode Institute is pleased to announce that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator Edwin Cuppen (UMC Utrecht), in collaboration with clinicians Filip de Vos (medical oncologist at UMC Utrecht) and Marike Broekman (neurosurgeon at Haaglanden MC), will investigate the added value of whole genome sequencing on tumor tissue obtained from glioblastoma patients during a routine operation for a first relapse after standard treatment with chemo– and radiotherapy.
26 May 2021
New Oncode Facility UFO Biosciences available for Oncode Researchers
Together with her team, Oncode Investigator Miao-Ping Chien (Erasmus MC) created a novel microscope-based technique to investigate cells. Under the name UFO Biosciences, Chien and her team offer services to microscopically screen cell populations, identify cells of interest based on imageable phenotypes and then isolate and profile these cells to link these phenotypes of interest to their driving genotypes.
14 April 2021
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboud University) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
13 April 2021
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
1 April 2021
'Live' measurements of cell signals show need for combination therapy in colorectal cancer
The team of Oncode Investigator Hugo Snippert (UMC Utrecht) has succeeded in using organoid technology to monitor live how a colon tumor responds to a combination therapy. The results appear today, April 1st, in the leading journal Nature Cell Biology.
Scroll for more